Correlation of peripheral blood miR-29b, FGF23, and ADP levels with disease progression and bone metabolism disorders in patients with chronic kidney disease
10.3760/cma.j.cn431274-20240613-00938
- VernacularTitle:外周血miR-29b、FGF23、ADP水平与慢性肾脏病患者病情发展及骨代谢紊乱的相关性
- Author:
Zhe WANG
1
;
Bei XIAO
1
;
Lei HUANG
1
Author Information
1. 合肥市第一人民医院肾内科，合肥 230038
- Publication Type:Journal Article
- Keywords:
Chronic kidney disease;
Micro RNA-29b;
Fibroblast growth factor 23;
Adiponectin;
Disordered bone metabolism
- From:
Journal of Chinese Physician
2025;27(9):1350-1354
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between peripheral blood microRNA-29b (miR-29b), fibroblast growth factor 23 (FGF23), adiponectin (ADP) and disease progression as well as bone metabolism disorders in patients with chronic kidney disease (CKD).Methods:A total of 106 CKD patients diagnosed in the Department of Nephrology, the First People′s Hospital of Hefei from February 2022 to February 2024 were selected as the CKD group, and 103 healthy subjects who underwent physical examination during the same period were selected as the control group. Differences in peripheral blood miR-29b, ADP, FGF23, serum calcium, serum phosphorus, alkaline phosphatase (ALP), 25-hydroxyvitamin D, and renal function levels between the two groups were compared. The CKD group was stratified according to CKD stages, and the above indicators were compared. Simple linear correlation analysis was used to analyze the correlation between miR-29b, ADP, FGF23 and bone metabolism indicators.Results:The levels of peripheral blood ADP and FGF23 in the CKD group were higher than those in the control group, while the level of miR-29b was lower, with statistically significant differences (all P<0.05). The levels of serum phosphorus, ALP, serum creatinine, and 24-hour urinary protein in the CKD group were higher than those in the control group, while the levels of serum calcium and 25-hydroxyvitamin D were lower, with statistically significant differences (all P<0.05). Among the 106 CKD patients, there were 8 cases in CKD stage 1, 22 in stage 2, 38 in stage 3, 32 in stage 4, and 6 in stage 5. The levels of peripheral blood ADP and FGF23 in patients with CKD stages 4-5 were higher than those in patients with CKD stages 1-3, while the level of miR-29b was lower, with statistically significant differences (all P<0.05). The levels of serum phosphorus, ALP, serum creatinine, and 24-hour urinary protein in patients with CKD stages 4-5 were higher than those in patients with CKD stages 1-3, while the levels of serum calcium and 25-hydroxyvitamin D were lower, with statistically significant differences (all P<0.05). In CKD patients, peripheral blood miR-29b was positively correlated with serum calcium and 25-hydroxyvitamin D (all P<0.05), and negatively correlated with ALP ( P<0.05). Peripheral blood ADP in CKD patients was negatively correlated with serum calcium ( P<0.05) and positively correlated with ALP ( P<0.05). Peripheral blood FGF23 in CKD patients was negatively correlated with serum calcium ( P<0.05) and positively correlated with ALP ( P<0.05). Conclusions:The levels of peripheral blood ADP and FGF23 in CKD patients are significantly increased, and the level of miR-29b is significantly decreased, which are related to disease progression and bone metabolism disorders in CKD patients.
